Customize View
Named by Company
Named by Competitor
Named by Third Party

Recently disclosed competitors only (within the last two years)
Include Competitors for:Current subsidiaries


Competitors

Recently Disclosed Competitors
Competitor's Name
LTM Revenue ($mm)
LTM Date
Source
Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH)
540.89
Jun-30-2023
Emergent BioSolutions Inc. (NYSE:EBS) 2023 Form 10-K
Business Description: Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors’ offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
AngioDynamics, Inc. (NasdaqGS:ANGO)
335.89
Aug-31-2023
AngioDynamics, Inc. (NasdaqGS:ANGO) 2023 Form 10-K
Business Description: AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company’s thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
Becton, Dickinson and Company (NYSE:BDX)
19,046.00
Jun-30-2023
AngioDynamics, Inc. (NasdaqGS:ANGO) 2023 Form 10-K
Business Description: Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company’s BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company’s BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
biolitec AG
40.81
Jun-30-2014
AngioDynamics, Inc. (NasdaqGS:ANGO) 2015 Form 10-K
Business Description: biolitec AG, together with its subsidiaries, is engaged in the research, development, production, and sale of medical laser systems and accessories primarily in Europe and the United States. It offers fibers, lasers, and accessories for various therapeutic areas, such as phlebology, urology, coloproctology, gynecology, thoracic surgery, orthopedics, and ENT surgery, as well as provides photodynamic therapy with FOSCAN drugs for cancer treatment. The company’s products include biolitec lasers, such as LEONARDO laser that is used for ENT surgery, phlebology, coloproctology, urology, and gynecology treatment; and Ceralas HPD laser system for use in thoracic surgery and gynecology treatment; Ceralas laser system for use in orthopedics and urology therapeutic areas; and PLDD Kits, which is used in orthopedics treatment. It also offers biolitec fibers, including XCAVATOR, MyoFiber, and PolyFiber; ELVeS Radial fibers and kits for use in the Phlebology treatment; LHP and FiLaC fibers and kits, which are used for the treatment of hemorrhoids and the removal of fistulas; and EVOLVE lasers for use in the thoracic surgery and orthopedics treatment, as well as provides fibers for LEONARDO, Ceralas, holmium lasers, and handpieces and instruments. The company was founded in 1999 and is based in Vienna, Austria. biolitec AG operates as a subsidiary of Biomed Technology Holdings Ltd.
Boston Scientific Corporation (NYSE:BSX)
13,400.00
Jun-30-2023
AngioDynamics, Inc. (NasdaqGS:ANGO) 2023 Form 10-K
Business Description: Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
C. R. Bard, Inc.
3,875.40
Sep-30-2017
AngioDynamics, Inc. (NasdaqGS:ANGO) 2018 Form 10-K
Business Description: C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and invasive devices for treating peripheral vascular and end-stage renal diseases. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for treating prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; surgical slings and pelvic floor repair products; catheter stabilization devices; and products for therapeutic hypothermia. In addition, the company offers oncology products, such as specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices to treat and manage various cancers, and other diseases and disorders. Further, it provides surgical specialty products comprising implanted grafts and fixation devices for hernia and soft tissue repairs; and hemostats and surgical sealants, as well as irrigation, wound drainage, and original equipment manufacturers’ products. The company sells its products directly to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities through hospital/surgical supply and other medical specialty distributors. C. R. Bard, Inc. was founded in 1907 and is headquartered in Murray Hill, New Jersey. As of December 29, 2017, C. R. Bard, Inc. operates as a subsidiary of Becton, Dickinson and Company.
Cook Medical Incorporated
-
-
AngioDynamics, Inc. (NasdaqGS:ANGO) 2023 Form 10-K
Business Description: Cook Medical Incorporated designs, manufactures, and distributes minimally invasive medical devices for diagnostic and therapeutic procedures in the United States and internationally. Its products include catheters, wire guides, introducer sheaths, stents, embolization coils, vena cava filters, aortic endovascular grafts, airway management devices, central venous catheter devices, and drainage products. The company also provides FluoroSet, a radiographic tubal assessment set to deliver fluoroscopic evaluation results; and histology needles for endoscopic ultrasound. In addition, it develops Hercules 3 Stage Esophageal Balloon to treat gastrointestinal structures; NavAlign delivery system, a deployment system designed to minimize the risk of vessel trauma and streamline filter placement; Cantata superselective microcatheters; deflecting endoscopic system that enables physicians to manage a stone case with only Cook products, and for use in other kidney and bladder procedures; enteral feeding products that are used for gastrostomy feeding; and Flourish Pediatric Esophageal Atresia device for the treatment of pediatric esophageal atresia. The company’s products are used for cardiovascular surgery; electrophysiology; radiology, neurosurgery; oncology; plastic and reconstructive surgery; endovascular therapy; critical care medicine; general surgery; diagnostic and interventional procedures; bioengineered tissue replacement and regeneration; pulmonary medicine; thoracic surgery; gastroenterology and endoscopy procedures; urology; and obstetrics and gynecology. It integrates medical devices, drugs, and biologics to enhance patient safety and improve clinical outcomes. The company caters to hospitals, doctors, and healthcare providers. Cook Medical Incorporated was founded in 1963 and is based in Bloomington, Indiana with additional offices in Canton, Illinois; and Vandergrift, Pennsylvania. Cook Medical Incorporated operates as a subsidiary of Cook Group Incorporated.
DMK Pharmaceuticals Corporation (NasdaqCM:DMK)
5.02
Jun-30-2023
Emergent BioSolutions Inc. (NYSE:EBS) 2023 Form 10-K
Business Description: DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company’s lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California.
Emergent BioSolutions Inc. (NYSE:EBS)
1,073.70
Jun-30-2023
Emergent BioSolutions Inc. (NYSE:EBS) 2023 Form 10-K
Business Description: Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; public health crises; and acute, emergency, and community care. The company offers ACAM2000, a smallpox vaccine; Anthrasil to for inhalational anthrax; Botulism Antitoxin Heptavalent to treat botulinum disease; BioThrax, an anthrax vaccine; Ebanga, a monoclonal antibody to treat infection caused by Zaire ebolavirus; raxibacumab injection for the treatment of inhalational anthrax; reactive skin decontamination lotion kits; TEMBEXA for the treatment of human smallpox disease; Trobigard, an auto-injector atropine sulfate and obidoxime chloride auto-injector for the emergency treatment of known or suspected exposure to nerve agents; and vaccinia immune globulin intravenous that addresses complications from smallpox vaccine. It also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, the company is developing AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; EBS-LASV; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Hikma Pharmaceuticals PLC (LSE:HIK)
2,731.00
Jun-30-2023
Emergent BioSolutions Inc. (NYSE:EBS) 2023 Form 10-K
Business Description: Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company was founded in 1978 and is headquartered in London, the United Kingdom.
Inari Medical, Inc. (NasdaqGS:NARI)
439.15
Jun-30-2023
AngioDynamics, Inc. (NasdaqGS:ANGO) 2023 Form 10-K
Business Description: Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy systems for the specific disease states in the United States. The company provides ClotTriever, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Johnson & Johnson (NYSE:JNJ)
98,656.00
Oct-01-2023
AngioDynamics, Inc. (NasdaqGS:ANGO) 2023 Form 10-K
Business Description: Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company’s Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
kaleo, Inc.
10.75
-
Emergent BioSolutions Inc. (NYSE:EBS) 2022 Form 10-K
Business Description: kaleo, Inc. develops, markets, and sells pharmaceutical and medical products. The company offers drug, device development, and human factors engineering (HFE) services. Its product includes AUVI-Q 0.1 mg, an epinephrine auto-injector specifically designed for the treatment of life-threatening allergic reactions in infants and small children weighing 16.5 to 33 pounds; and EVZIO, a naloxone HCl injection. The company offers its products through distributors in the United States and Canada. kaleo, Inc. was formerly known as Intelliject, Inc. and changed its name to kaleo, Inc. in December 2013. The company was founded in 2005 and is based in Richmond, Virginia.
Koninklijke Philips N.V. (ENXTAM:PHIA)
19,348.99
Jun-30-2023
AngioDynamics, Inc. (NasdaqGS:ANGO) 2023 Form 10-K
Business Description: Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding, baby monitors, and digital parental solutions; and grooming and beauty products and solutions. It has strategic partnership agreements with TriHealth, Prisma Health, and the University Health System of San Antonio to help the health system standardize patient monitoring, drive interoperability, and lay the foundation for enterprise-wide platform; and Oulu University Hospital to deliver advanced image-guided therapy solutions. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
Medical Components, Inc.
47.52
-
AngioDynamics, Inc. (NasdaqGS:ANGO) 2023 Form 10-K
Business Description: Medical Components, Inc. engages in the research, development, manufacture, and supply of vascular access devices and accessories for interventional medicine and dialysis. It offers a range of vascular access catheters; and accessories, such as needles, repair kits, dilators, guidewires, sheath dilators, and trocars and tunnelers for acute, long term, and short term hemodialysis, as well as central vein infusion and peritoneal dialysis applications. The company serves the clinical needs of the medical industry. It sells its products through direct-sales force. The company was founded in 1978 and is based in Harleysville, Pennsylvania.
Medtronic plc (NYSE:MDT)
31,558.00
Jul-28-2023
AngioDynamics, Inc. (NasdaqGS:ANGO) 2023 Form 10-K
Business Description: Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company’s Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company’s Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Merit Medical Systems, Inc. (NasdaqGS:MMSI)
1,198.21
Jun-30-2023
AngioDynamics, Inc. (NasdaqGS:ANGO) 2023 Form 10-K
Business Description: Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy. It operates in two segments, Cardiovascular and Endoscopy. The company provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate strictures; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
Smiths Medical, Inc.
1,006.56
-
AngioDynamics, Inc. (NasdaqGS:ANGO) 2021 Form 10-K
Business Description: Smiths Medical, Inc. engages in the research and development, manufacture, and sale of infusion therapy, vascular access, vital care, and specialty products and services for use in hospital, emergency, home, and specialty care environments. It offers airway management products that include anesthesia breathing circuits, anesthesia masks, endotracheal tubes and laryngeal masks, and carbon dioxide absorbents, and infusion systems that include pumps, disposables, and software. The company also provides interventional imaging products for interventional radiology and cardiology needs, pain management and regional anesthesia systems and devices, vital signs monitoring devices for use in a range of inpatient and outpatient environments, and pressure monitoring systems for operating rooms, critical care units, labor and delivery, and catheterization labs. In addition, it offers airway management and therapeutic devices for respiratory care, including tracheostomy tubes and accessories, arterial blood gas systems, bronchial hygiene, lung expansion products, active humidification and nebulization systems, open manual resuscitators, passive humidification products, and filtration products, and oxygen/aerosol masks, cannulas, tubing, and nebulizers. Further, the company provides a range of safety devices, such as hypodermics, insulin and TB syringes, peripheral intravenous catheters, venipuncture, winged needle draws, closed system procedures, lancet sampling products, and arterial blood sampling products, temperature management products, tracheostomy products, and ventilators. It serves customers directly, and through distribution arrangements in the Unites States and internationally. Smiths Medical, Inc. was formerly known as Portland Plastics. The company was founded in 1940 and is based in Minneapolis, Minnesota. As of January 6, 2022, Smiths Medical, Inc. operates as a subsidiary of ICU Medical, Inc.
Terumo Medical Corporation
372.18
-
AngioDynamics, Inc. (NasdaqGS:ANGO) 2023 Form 10-K
Business Description: Terumo Medical Corporation manufactures medical devices and supplies. It offers interventional systems, medical products, and pharmaceutical solutions. The company also provides services to cardiac cath labs. It serves customers worldwide. Terumo Medical Corporation was formerly known as Kimble-Terumo, Inc. and changed its name to Terumo Medical Corporation in August 1980. The company was founded in 1972 and is headquartered in Somerset, New Jersey with locations in the United States and internationally. Terumo Medical Corporation operates as a subsidiary of Terumo Corporation.
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
15,017.00
Jun-30-2023
Emergent BioSolutions Inc. (NYSE:EBS) 2023 Form 10-K
Business Description: Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company’s products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington’s disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration with MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia, as well as a collaboration with Sanofi to co-develop and co-commercialize TEV-48574 asset, a novel anti-TL1A therapy for the treatment of ulcerative colitis and Crohn’s disease. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
Total Vein Solutions, LLC
4.33
-
AngioDynamics, Inc. (NasdaqGS:ANGO) 2023 Form 10-K
Business Description: Total Vein Solutions, LLC doing business as Total Vein Systems manufactures and markets venous surgery packs, laser fibers, access devices, and surgical supplies. The company products include reusable laser fibers; micro, long, and one-step introducer kits; universal, custom, dressing, specialty, and microphlebectomy packs; microphlebectomy hooks; specialty items, such as ultrasound probe covers, access needles, drapes, gowns, towels, bandages and dressings, wound care products, laser re-use tools, guidewires, syringe delivery kits, sigvaris stockings, and light sources; and sclerotherapy supplies. The company was founded in 2003 and is based in Houston, Texas. On January 17, 2008, Total Vein Solutions LLC filed a voluntary petition for reorganization under Chapter 11 in the United States bankruptcy court for the Southern District of Texas.
Varian Medical Systems, Inc.
3,118.10
Jan-01-2021
AngioDynamics, Inc. (NasdaqGS:ANGO) 2023 Form 10-K
Business Description: Varian Medical Systems, Inc. designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide. It operates through the Oncology Systems and Proton Solutions segments. The Oncology Systems segment offers hardware and software products for treating cancer with radiotherapy, fixed-field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy, artificial intelligence-based adaptive radiotherapy, and brachytherapy, as well as quality assurance equipment. Its products include linear accelerators, brachytherapy afterloaders, treatment accessories, and quality assurance software; and information management, treatment planning, image processing, clinical knowledge exchange, patient care management, decision-making support, and practice management software. This segment serves university research and community hospitals, private and governmental institutions, healthcare agencies, physicians’ offices, medical oncology practices, radiotherapy centers, and cancer care clinics. The company has a strategic agreement with McKesson Corp. to supply treatment delivery systems and planning, services, and radiotherapy information system solutions to its U.S. Oncology Network and Vantage Oncology affiliated sites of care; strategic partnership with Siemens AG to represent Siemens diagnostic imaging products to radiation oncology clinics in the United States and other select markets; and collaboration with Google Cloud. Varian Medical Systems, Inc. was formerly known as Varian Associates, Inc. and changed its name to Varian Medical Systems, Inc. in April 1999. The company was founded in 1948 and is headquartered in Palo Alto, California. As of April 15, 2021, Varian Medical Systems, Inc. operates as a subsidiary of Siemens Healthineers AG.
Vascular Solutions, Inc.
166.57
Dec-31-2016
AngioDynamics, Inc. (NasdaqGS:ANGO) 2016 Form 10-K
Business Description: Vascular Solutions, Inc., a medical device company, provides clinical solutions for treating coronary and peripheral vascular disease worldwide. The company’s primary products include GuideLiner guide extension catheter device for use in complex interventions; Pronto extraction catheters for treating acute myocardial infarction; vein catheter reprocessing service for the radiofrequency vein ablation catheter; and micro-introducer kits that are used to gain percutaneous access to the vasculature to perform minimally invasive procedures. Its products also comprise hemostatic patches consisting of blood clotting products, such as the D-Stat Dry hemostat, a topical thrombin-based pad with a bandage used to control surface bleeding; radial access products, including the Accumed wrist positioning splints and Vasc Band inflatable compression bands; Langston catheter used for the measurement of intravascular pressure gradients, primarily to diagnose aortic valve stenosis; and D-Stat Flowable hemostat that is used to control active bleeding. The company sells its products through direct sales force and distributor to interventional cardiologists, interventional radiologists, electrophysiologists, and vein specialists. Vascular Solutions, Inc. was founded in 1996 and is headquartered in Minneapolis, Minnesota. As of February 17, 2017, Vascular Solutions, Inc. operates as a subsidiary of Teleflex Incorporated.
*denotes proprietary relationship